HOME >> BIOLOGY >> NEWS
Brookhaven scientists determine key Lyme disease protein structure

structure.

John Dunn, a member of the research team from Brookhaven, explains that the structure of OspC is predominantly helical, and very different from OspA, which is flat. Also, a region on the surface of OspC has a strong negative charge. Dunn says the negatively charged region may be attracted to a positively charged site on the surface of human cells, helping the bacterium to cause infection. This feature is only found in the OspC protein derived from bacterial strains that cause human disease.

The scientists believe that a vaccine based on OspC will be more effective than the current OspA-based vaccine because the OspA protein is only present in the bacteria while they are in the cold-blooded deer ticks stomach, and not in the host. After the tick bites the warm-blooded mammalian host, the injected bacteria produce OspC in the hosts bloodstream.

When the host is vaccinated solely with OspA, antibodies to this protein can only kill the bacterium inside the tick if it ingests these antibodies with its blood-meal. If the bacterium finds its way into the host, it changes into several other forms for which the vaccine offers no protection.

In contrast, an OspC-based vaccine would enable the host to make antibodies to kill the Lyme disease bacteria within the hosts body.

Another member of the Brookhaven team, Subramanyam Swaminathan, added, In order to develop an effective OspC-based vaccine, well have to know the three-dimensional structures of at least a few variants of OspC, especially those from invasive strains. Since weve solved the structure of OspC based on two infectious strains of the Lyme disease bacterium, we now have a prototype for determining the structure of OspC from other strains.


'"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
27-Feb-2001


Page: 1 2

Related biology news :

1. Brookhaven lab biophysicist F. William Studier wins R&D 100 award
2. Workshop for new synchrotron light source at Brookhaven
3. Brookhaven Lab expects $30 million to support life sciences
4. Brookhaven Lab develops ThraxVac to clean up anthrax
5. Brookhaven Lab & Battelle collaborate on research that may lead to novel anti-microbial drugs
6. Rice, Brookhaven physicists decode initial stage of cell fusion
7. Brookhaven Lab scientist wins Environmental Mutagen Society Award
8. Brookhaven Spotlights: News from the National Synchrotron Light Source
9. Enzyme studies at Brookhaven Lab may lead to new antiviral agents
10. New Brookhaven Lab study shows how ritalin works
11. New test for radiation damage to DNA developed at Brookhaven Lab

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
Cached News: